Search research articles
Contact Us
Filters
Showing results (71-80 of 81) with videos related to
Page
of 9
Sort By:
ESMO Open
|
May 13, 2021
Impact of the 12-gene recurrence score assay on deciding adjuvant chemotherapy for stage II and IIIA/B colon cancer: the SUNRISE-DI study
E Oki, J Watanabe, T Sato, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 26, 2013
Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912
Y Yamada, N Boku, T Nishina, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study
K Nakanishi, N Sugimoto, Y Kodera, et al.
ESMO Open
|
December 12, 2022
A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)
W Okamoto, K Sakai, A Makiyama, et al.
ESMO Open
|
May 27, 2026
Effect of prior anti-EGFR therapy and baseline ctDNA profiling on the efficacy of pertuzumab plus trastuzumab in HER2-amplified metastatic colorectal cancer: an integrated analysis of TRIUMPH/MyPathway
Y Matsubara, M Wakabayashi, W Okamoto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 16, 2014
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer
Y Yamada, K Higuchi, K Nishikawa, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Association of PD-L1 and PD-L2 expression and tumor-infiltrating lymphocytes in <i>BRAF</i> V600E-mutated metastatic colorectal cancer: GI-SCREEN <i>post-hoc</i> analysis
M Imai, Y Nakamura, T Denda, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD)
K Shimozaki, K Hirata, H Hayashi, et al.
ESMO Open
|
October 10, 2025
A multicenter phase II study of eribulin for BRAF V600E mutant metastatic colorectal cancer: the BRAVERY study (EPOC1701)
T Masuishi, H Taniguchi, D Kotani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 9, 2020
Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials
T Yoshino, J M Cleary, E Van Cutsem, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 81) with videos related to
Sort By:
Page
of 9
ESMO Open
|
May 13, 2021
Impact of the 12-gene recurrence score assay on deciding adjuvant chemotherapy for stage II and IIIA/B colon cancer: the SUNRISE-DI study
E Oki, J Watanabe, T Sato, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 26, 2013
Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912
Y Yamada, N Boku, T Nishina, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study
K Nakanishi, N Sugimoto, Y Kodera, et al.
ESMO Open
|
December 12, 2022
A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)
W Okamoto, K Sakai, A Makiyama, et al.
ESMO Open
|
May 27, 2026
Effect of prior anti-EGFR therapy and baseline ctDNA profiling on the efficacy of pertuzumab plus trastuzumab in HER2-amplified metastatic colorectal cancer: an integrated analysis of TRIUMPH/MyPathway
Y Matsubara, M Wakabayashi, W Okamoto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 16, 2014
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer
Y Yamada, K Higuchi, K Nishikawa, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Association of PD-L1 and PD-L2 expression and tumor-infiltrating lymphocytes in <i>BRAF</i> V600E-mutated metastatic colorectal cancer: GI-SCREEN <i>post-hoc</i> analysis
M Imai, Y Nakamura, T Denda, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD)
K Shimozaki, K Hirata, H Hayashi, et al.
ESMO Open
|
October 10, 2025
A multicenter phase II study of eribulin for BRAF V600E mutant metastatic colorectal cancer: the BRAVERY study (EPOC1701)
T Masuishi, H Taniguchi, D Kotani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 9, 2020
Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials
T Yoshino, J M Cleary, E Van Cutsem, et al.
Page
of 9